Drug Profile
Research programme: T-type calcium channel modulators - Jazz Pharmaceuticals plc
Alternative Names: TTL-1177Latest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator Tau Therapeutics
- Developer Cavion
- Class Antineoplastics; Small molecules
- Mechanism of Action T type calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 Dec 2022 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 12 Aug 2019 Cavion has been acquired by Jazz Pharmaceuticals plc